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Influence of ketanserin on experimental loss of renal blood flow
autoregulation. Serotonin is important for effective renal blood
flow (RBF) autoregulation in the normal rat and at two or seven
days of reperfusion following renal ischemia. It has been sug-
gested that after these reperfusion periods and during renal
perfusion pressure (RPP) lowering, the vasodilatory autoregula-
tion mechanism is not damaged but overwhelmed by increased
5-HT2-mediated vasoconstriction, resulting in complete loss of
autoregulation. This study analyzes the influence of the 5-HT2-
antagonist ketanserin on RBF autoregulation after two hours or
one day of renal reperfusion following ischemia and in a model of
cyclosporine (20 mg/kg.day for 10 days)-induced nephrotoxicity.
Autoregulation was lost both after brief reperfusion periods and
after cyclosporine. Similar to the two or seven days of reperfusion
experiments, ketanserin in the cyclosporine model led to reap-
pearance of autoregulation down to RPP 95 mm Hg. Despite an
increased response to intrarenal serotonin after two hours of
reperfusion, autoregulation was not restored by ketanserin. At
one day of reperfusion and with ketanserin, autoregulation was
present down to 105 mm Hg. Thus, during the early reflow period,
other factors (of decreasing importance) most likely add to
autoregulation loss.
A well-known and important characteristic of regulation
of renal function is autoregulation of renal blood flow
(RBF) and glomerular filtration rate (GFR). RBF autoreg-
ulation is due largely to myogenic responses in preglomeru-
lar arteries [1, 2]. Within the autoregulatory renal perfusion
pressure (RPP) range, vasodilation maintains RBF when
RPP is lowered.
Serotonin [5-hydroxytryptamine (5-HT)], whether re-
leased from aggregating platelets or formed locally in the
kidney or from an exogenous source, can modulate the
contractile activity of vascular smooth muscle cells
(VSMCs) [3]. Serotonergic 5-HT2 receptors are present on
VSMCs, and their activation leads to vasoconstriction; the
endothelial 5-HT1 receptor is involved in the release of
nitric oxide and elicits vasodilation [4]. The 5-HT2-receptor
blocker ketanserin [5] not only increases RBF and GFR in
normal rats, but also preserves RBF autoregulation to
RPPs as low as 70 to 75 mm Hg [6], far below the normal
limit of 90 to 95 mm Hg. In the split hydronephrotic rat
kidney, basal preglomerular 5-HT2 vasoconstriction activity
is present, and 5-HT administration impairs GFR autoreg-
ulation [7]. These data indicate that 5-HT2 receptor acti-
vation is important for regulation of normal rat renal
hemodynamics and led us to study the potential role of
5-HT in the loss of autoregulation after renal ischemia or
cyclosporine-induced nephrotoxicity.
In patients [8] and in models of experimental acute renal
failure (ARF) induced by renal artery occlusion [9] or
intrarenal norepinephrine [9, 10], even short insults of
subsequent renal hypoperfusion after ischemic ARF led to
recurrent renal damage. Lack of RBF autoregulation,
hence of protection against repeated falls in RPP, may play
a role in these successive insults. Loss of RBF autoregula-
tion has been reported in some models of postischemic
ARF [11, 12] and in some animal models of subchronic
cyclosporine treatment [13, 14]. Cyclosporine-induced re-
nal dysfunction is due primarily to hemodynamic effects
resulting in a fall of RBF and GFR [15]. The loss of
autoregulation in cyclosporine-induced ARF makes the
kidney vulnerable to hypoperfusion damage and hence to
ischemia. A contribution of ischemia to cyclosporine-in-
duced renal damage has been suggested [16–18].
KETANSERIN AND AUTOREGULATION IN
POSTISCHEMIC CONDITIONS
Renal blood flow autoregulation is lost in rats at two- or
seven days of reperfusion after 40-minutes unilateral renal
artery clamping. Acute administration of ketanserin re-
stores autoregulation at both times but does not ameliorate
the fall in GFR or influence fractional sodium excretion
[11]. Although ketanserin also has a1-adrenergic blocking
characteristics [6, 11, 19], the dose used in our studies in
normal [6] or postischemic rats (0.05 mg/kg i.v. bolus,
followed by 0.1 mg/kg.hr infusion) [11] was devoid of
a1-blocking actions. These studies imply that the vasodila-
tory autoregulation mechanism per se is not impaired but
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that autoregulation is rather suppressed by enhanced
5-HT2 influence at two or seven days of reflow. 5-HT might
thus be an important determinant of the effective autoreg-
ulation range, both in control rats and after experimental
renal ischemia/reperfusion damage [11].
To understand better the beneficial influence of ketan-
serin on autoregulation loss in the renal artery clamp
model, the possible importance of Ca21 has been explored.
As well as structural vascular alterations such as VSMC
necrosis [11, 12, 20], adventitial fibrosis [12], hypersensitiv-
ity to renal nerve stimulation [20], and loss of response to
endothelium-dependent vasodilators [20], accumulation of
Ca21 in VSMCs could cause aberrant renovascular func-
tion in postischemic conditions [21]. Two chemically dis-
similar Ca21 entry blockers, verapamil and diltiazem, have
beneficial effects on autoregulatory responses after norepi-
nephrine-induced ischemic ARF [21].
We thus examined the influence of verapamil on RBF
autoregulation loss two or seven days after ischemia. After
confirming loss of autoregulation, verapamil was given i.v.
(0.8 mg/kg bolus plus 20 mg/kg.min infusion) or intrare-
nally (i.r. infusion of 4 mg/kg.min; that is, the maximal
dose without systemic effects). Preliminary experiments
showed that the i.v. dose significantly attenuated but did
not block the vasoconstrictor response to i.r. phenylephrine
or 5-HT, with minimal alteration of mean arterial pressure.
After one hour of verapamil, another autoregulation curve
was obtained, while the infusion was continued. Figure 1A
Fig. 1. Renal blood flow (RBF; percentage of initial flow) as a function of renal perfusion pressure. Means 6 SEM. (A) Control autoregulation curve
(F) before 40-minutes unilateral renal artery clamping (ischemia; RBF 5.15 6 0.58 ml/min at 115 mm Hg), at two days of reperfusion (f; RBF 4.08
6 0.65 ml/min at 115 mm Hg), at two days of reperfusion and verapamil (; RBF 4.85 6 0.7 ml/min at 115 mm Hg; N 5 6). *P , 0.05 control versus
two days of reperfusion. §P , 0.05, control versus two days of reperfusion and verapamil. (B) Control autoregulation curve (M) before ischemia (RBF
4.75 6 0.28 ml/min at 115 mm Hg), at two hours of reperfusion and ketanserin (f; RBF 3.69 6 0.29 ml/min at 115 mm Hg; N 5 6). *P , 0.05, control
versus two hours of reperfusion. (C) At one day of reperfusion before ketanserin (M; RBF 3.58 6 0.16 ml/min at 115 mm Hg), after ketanserin (f; RBF
3.78 6 0.18 ml/min at 115 mm Hg; N 5 5). *P , 0.05, before versus after ketanserin. (D) In cyclosporine-treated rats before ketanserin (M; RBF 3.59
6 0.24 ml/min at 110 mm Hg), after ketanserin (f; RBF 3.95 6 0.35 ml/min at 110 mm Hg; N 5 8). *P , 0.05, before versus after ketanserin. Curves
were obtained All comparisons on a point-to-point basis.
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shows the changes in RBF in response to progressive RPP
reduction in controls and at two days of reperfusion before
and after i.v. administration of verapamil. Verapamil sig-
nificantly increased basal RBF, but RBF autoregulation
was still absent. Similar results were obtained at seven days
of reflow and after i.r. verapamil (not shown). These results
are contrary to those from the norepinephrine model [21].
The fact that the latter is characterized predominantly by
functional endothelial damage, whereas a renal artery
clamp model is characterized mainly by morphological and
functional VSMC damage, might help explain this discrep-
ancy [20].
The question remained whether the 5-HT2-mediated
influence on the expression of RBF autoregulation, found
in control kidneys as well as two or seven days postisch-
emia, is also present at shorter reperfusion periods. In
conscious rats, the 5-HT2-antagonistic activity of levemo-
pamil improved renal function after a rather brief reperfu-
sion period following ischemia [23]. We thus examined
RBF autoregulation and the influence of ketanserin at two
hours or one day following unilateral renal artery clamping.
After two hours of reflow, RBF autoregulation was absent
in all animals and was not restored by ketanserin (given for
1 hr; Fig. 1B). However, i.r. 5-HT injection elicited a
significantly greater RBF decrease, implying increased
5-HT2-mediated vasoconstriction at two hours of reperfu-
sion. These data suggest that perhaps other factors are
responsible for autoregulation loss in this early reperfusion
period.
Autoregulation was still completely absent after ischemia
and one day of reperfusion. A one hour of ketanserin
administration partly restored autoregulation: The percent-
age RBF improved significantly for RPPs between 110 and
95 mm Hg. Contrary to the two hours of reperfusion, which
showed no plateau, regression analysis of the data one day
after ischemia and with ketanserin showed a plateau be-
tween 115 and 105 mm Hg (Fig. 1C). Taken together, it
seems that the impact of unknown factors suppressing
autoregulation at two hours of reflow becomes less impor-
tant with longer reperfusion. Only after two days of reper-
fusion is an autoregulation setpoint of 95 mm Hg apparent
after 5-HT2-antagonism, as found previously [11].
KETANSERIN AND AUTOREGULATION AFTER
CYCLOSPORINE TREATMENT
5-HT may also be important in alterations of renal
hemodynamics seen after cyclosporine [24]. Simultaneous
administration of cyclosporine with ketanserin protects
renal function [25], although ketanserin’s possible influence
on the loss of autoregulation after cyclosporine was not
considered.
We thus examined the effect of ketanserin on the loss of
autoregulation in cyclosporine-induced nephrotoxicity (20
mg cyclosporine/kg/day orally for 10 days, leading to a
lowered RBF and GFR) [14]. At day 11, RBF autoregula-
tion was lost in all animals. Ketanserin acutely restored
RBF autoregulation (Fig. 1D) as after renal ischemia [11].
Thus, in this nephrotoxic model also, the vasodilatory
autoregulation mechanism itself seems not to be impaired,
but is rather overwhelmed by a stronger vasoconstriction
that can be abolished by ketanserin.
In conclusion, 5-HT seems to influence the effective
range of RBF autoregulation in the normal rat kidney. It is
even more important in experimental ARF following isch-
emia by renal artery clamping and in a model of subchronic
cyclosporine treatment, although it may not be the sole
factor suppressing RBF autoregulation. The persistent
renal postischemic vasoconstriction is diminished by Ca21
antagonists, but in the renal artery clamp model at least,
RBF autoregulation at two- or seven days of reperfusion
could not be restored.
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